Lists of people executed in the United States

Steel River Group and Trans-Pacific Trading Ltd. Partner to Build Indigenous Capacity in the Wood Products Sector

Retrieved on: 
Tuesday, November 9, 2021
BC, Forestry, Industry, Culture, Pacific Northwest, Confederation of Indigenous Nationalities of Ecuador, Education, CEO, Ownership, Burns, Lists of people executed in the United States, Workforce, Company, Partnership, Indigenous peoples, GLOBE, Time, Marketing, Employment, Oil

Through this new Alliance Partnership, Steel River and TRAPA will work collaboratively to enhance economic opportunities within the wood products sector for Indigenous communities and companies, including ownership in forestry related assets.

Key Points: 
  • Through this new Alliance Partnership, Steel River and TRAPA will work collaboratively to enhance economic opportunities within the wood products sector for Indigenous communities and companies, including ownership in forestry related assets.
  • This is an exciting partnership for Steel River Group, with incredible economic potential for Indigenous Nations and groups, said Trent Fequet, founder and CEO of Steel River Group.
  • As part of the Steel River Ecosystem, TRAPA will provide employment and training opportunities for Indigenous peoples in the wood products sector, providing immediate and long-term benefits back to the community.
  • Steel River is proud to welcome TRAPA to the Steel River Ecosystem and looks forward to exploring economic and project-driven opportunities within the wood products sector.

Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan

Retrieved on: 
Tuesday, November 9, 2021
Histology, Population, Safety, MCC, Cancer, Nasdaq, Private Securities Litigation Reform Act, Therapy, Genetics, Security (finance), RAD52, Food, Trial of the century, Merkel-cell carcinoma, RAIN, Program, ICI, AACR, Neoplasm, Incidence, U.S. Securities and Exchange Commission, GLOBE, Conference, MANTRA, LPS, MDM2, ORR, Interest, Patient, Liposarcoma, RECIST, Ageing, Lists of people executed in the United States, Pharmaceutical industry

NEWARK, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced its plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double minute 2 (MDM2) inhibitor, as a monotherapy for the treatment of patients with Merkel cell carcinoma (MCC) refractory to immune checkpoint inhibition (ICI) in mid-2022.

Key Points: 
  • We are very excited about the recent preclinical data generated for milademetan in Merkel cell carcinoma, and believe the data warrant moving the program into a clinical study, said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • Rain will prioritize its financial resources towards a Phase 2 clinical trial of milademetan in MCC and replace the previously planned Phase 2 clinical trial of milademetan in intimal sarcoma.
  • Merkel cell carcinoma is a rare, aggressive type of skin cancer that frequently travels to other parts of the body.
  • Rain Therapeutics also anticipates commencing a Phase 2 clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma refractory to immune checkpoint inhibition (ICI), in mid-2022.

Steel River Group’s new entity Water Care Company receives Alberta Innovates grant funding for water pilot project in Stoney Nakoda First Nation

Retrieved on: 
Thursday, November 4, 2021
Research, Kashechewan First Nation, Quality of life, Technology, Indigenous peoples, Company, Industry, Center for Environmental Innovation in Roofing, STA, Partnership, Nation, Lists of people executed in the United States, Life, Water resources, CEO, Alberta Innovates, Bearspaw First Nation, Solution, Water, Employment, Drinking water, Ownership, GLOBE, Culture, Education, Oil, Renewable energy, Risk management

CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Steel River Group Ltd. (Steel River) is honoured to share that its new entity, Water Care Company (Water Care), has received funding from the Alberta Innovates Water Innovation Program for its first water treatment project in Stoney Nakoda First Nation.

Key Points: 
  • CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Steel River Group Ltd. (Steel River) is honoured to share that its new entity, Water Care Company (Water Care), has received funding from the Alberta Innovates Water Innovation Program for its first water treatment project in Stoney Nakoda First Nation.
  • Alberta Innovates has committed $328,089 to Water Care to focus on developing the pre-commercial prototype of its Clarification Technology at the Morley plant.
  • This investment will help Water Care continue to develop its water treatment technology while supporting opportunities for education, employment, social sovereignty and economic sustainability.
  • For more information about Water Care Company, visit www.watercarecompany.com
    Alberta Innovates is the provinces largest and Canadas first provincial research and innovation agency.

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

Retrieved on: 
Wednesday, November 3, 2021
PD, Disease, LUMO, Drug development, Transgender hormone therapy, New Enterprise Associates, Patient, Insurance, NASDAQ, Clinical, FDA, ISS, Private Securities Litigation Reform Act, NEA, Gestational age, UCB, SEC, Lists of people executed in the United States, Optimism, Growth hormone, Income, Quarter, SGA, Company, Risk, Clinical trial, Depreciation, Degenerative disease, Webcast, CEO, Turner syndrome, PEM, Coronavirus Scientific Advisory Board (Turkey), Research, Prader–Willi syndrome, GH, Idiopathic short stature, Therapy, GLOBE, Orphan, Fine chemical, Pharmaceutical industry, Public relations

AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ending September 30, 2021 and provided an update on clinical programs.

Key Points: 
  • AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ending September 30, 2021 and provided an update on clinical programs.
  • Lumos Pharma is in advanced discussions with key opinion leaders and our Clinical and Scientific Advisory Board to expand our LUM-201 pipeline.
  • Financial Results for the Quarter Ended September 30, 2021
    Cash Position Lumos Pharma ended the third quarter on September 30, 2021, with cash and cash equivalents totaling $100.7 million compared to $98.7 million on December 31, 2020.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  

Retrieved on: 
Wednesday, November 3, 2021
Fibrosis, Beth Israel Deaconess Medical Center, Liver disease, AASLD, University, Harvard Medical School, MPS, University of Florida, SGLT2, Association, Institute of Liver and Biliary Sciences, Type 2 diabetes, NAFLD, Metabolism, CET, Patient, Control, American Association for the Study of Liver Diseases, Asian Liver Center, Lists of people executed in the United States, Internet, PAN, Mucopolysaccharidosis, Clinical trial, Webcast, CEO, Hepatology, Program, T2D, Liver, News, Fatty liver disease, American Association, NASH, Euronext Paris, Q&A, Division, University Medical Center, CAP, Associate, Agenda, Fungiculture, Pharmaceutical industry, Management, Hospital, Dietary supplement

Following an introduction from Frdric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH.

Key Points: 
  • Following an introduction from Frdric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH.
  • As part of the program, there will be dedicated Q&A sessions.
  • The Agenda will be as follows:
    Speakers: Frederic Cren, CEO and cofounder of Inventiva Pharma and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva Pharma
    Speaker: Prof. Nezam Afdhal, Harvard Medical School in Boston, Massachusetts and Chief of Hepatology and Director of the Liver Center at Beth Israel Deaconess Medical Center
    Abstract #1: Lanifibranor treatment improves hepatic steatosis in patients with NASH, evaluated by histological grading and Controlled Attenuation Parameter (CAP)."
  • Speaker: Prof. Jorn Schattenberg, Director of the Metabolic Liver Research Program at the University Medical Center of Mainz, Germany
    Abstract #4: "Treatment response to the PAN-PPAR agonist lanifibranor in the NATIVE study: NASH resolution and fibrosis improvement are correlated."

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

Retrieved on: 
Tuesday, November 2, 2021
Safety, Lung, Annual general meeting, MD, Technology, University, Poster, SAN, U.S. Securities and Exchange Commission, University of Sydney, Immunotherapy, Neoplasm, Blacktown Hospital, Patient, Private Securities Litigation Reform Act, NASDAQ, Cancer, Society, SEC, University of California, San Francisco, Lists of people executed in the United States, PD-1, Annual report, Forward-looking statement, Company, Webcast, COVID-19, Society for Immunotherapy of Cancer, Etal, Securities & Exchange Commission of Pakistan, Risk, Toxicity, Population, Journal, Liver, SITC, Electroporation, Tumor microenvironment, DNA, Pharmaceutical industry, Vaccine

The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting.

Key Points: 
  • The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting.
  • TAVO recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity, and we look forward to the updated data at SITC 2021 in this highly refractory patient population."
  • Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
  • doi:10.1136/ jitc-2019-000398
    OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies.

University of Maryland Reveals New Dining Hall Name in Honor of Piscataway Tribe

Retrieved on: 
Monday, November 1, 2021
Research, Maryland Stadium, Indigenous peoples, University, Bureau of Indian Affairs, Native, Heritage Community Christian School (Brockville, Ontario), History, Partnership, LEED, Pulitzer, Governor of Maryland, Faculty, EQUAL Community Initiative, Silver, University of Maryland, College Park, Artifact, Heritage, History of the University of Maryland, College Park, Pulitzer Prize, Students' union, Multimedia, Lists of people executed in the United States, College Park, Culture, Entrepreneurship, Native Americans, Student, Interior design, Medicine

"The naming of our new dining hall in honor of the Piscataway people is a symbolic way in which we are ushering in a new era of inclusiveness at the University of Maryland.

Key Points: 
  • "The naming of our new dining hall in honor of the Piscataway people is a symbolic way in which we are ushering in a new era of inclusiveness at the University of Maryland.
  • Acknowledging our storied past is one of the most important steps in creating a community that is TerrapinSTRONG," said University of Maryland President Darryll J. Pines.
  • The new 60,000+-square-foot, 1,000-seat dining hall is the first building at UMD to honor the Native American heritage of its campus.
  • The University of Maryland, College Park is the state's flagship university and one of the nation's preeminent public research universities.

Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

Retrieved on: 
Monday, November 1, 2021
Diabetic retinopathy, American Society of Cataract and Refractive Surgery, LDP, Partnership, Private Securities Litigation Reform Act, NASDAQ, DME, FDA, Refractive surgery, NVD, SEC, Presbyopia, Review, Lists of people executed in the United States, Maintenance, American Academy of Ophthalmology, Light, COVID-19, DR, Risk, ASCRS, American Academy, Cataract, Society, Pharmaceutical industry

FARMINGTON HILLS, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that clinical data on its therapeutic candidates Nyxol® and APX3330 will be featured in poster sessions as presentations at the upcoming American Academy of Ophthalmology (AAO) 2021 annual meeting to take place in New Orleans, November 12 – 15. In addition, Ocuphire will present at the Eyecelerator@AAO 2021 satellite symposium on November 11.

Key Points: 
  • Ocuphire is part of a lineup of more than 30 companies, from startups to public, who will present innovations at all stages.
  • Ocuphire will be one of two companies presenting clinical data for Presbyopia at the meeting.
  • Ocuphire reported positive top-line data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM.
  • Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia.

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937

Retrieved on: 
Monday, November 1, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Event, RCC, FCCP, Critical care, Quality of life, Burn, University, BLU, Icahn School of Medicine at Mount Sinai, Risk, Bachelor of Medicine, Bachelor of Surgery, MB, Patient, Private Securities Litigation Reform Act, Investor, Chronic cough, Achievement, TSX, Review, Lists of people executed in the United States, Atopic dermatitis, Respiratory Medicine, Annual report, Forward-looking statement, Company, Intention, COVID-19, Environment, Irritation, AD, Health, EST, News, Pain, Nasdaq, Risk factor, U.S. Securities and Exchange Commission, FRCP, Therapy, Sensation, Doctor of Philosophy, Itch, Population, Legislation, Disorder, Mount Sinai, Pharmaceutical industry, BLU-5937, BELLUS Health (, BLU-5937, BELLUS HEALTH (

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders, today announced that it will convene a virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist, BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.

Key Points: 
  • BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders, today announced that it will convene a virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist, BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.
  • The live webcast of the event may be accessed through the Events & Presentations page of BELLUS Healths website, under the Investors & News section.
  • BLU-5937, a highly selective P2X3 antagonist, is in development for RCC, chronic pruritus and other hypersensitization-related disorders.
  • The P2X3 receptor, which is implicated in cough reflex hypersensitization, is a rational target for treating chronic cough, and it has been evaluated in multiple clinical trials with different P2X3 antagonists.

NANO 2 Meet You! VOOPOO DRAG NANO 2 is Launched with a Bang!

Retrieved on: 
Monday, November 1, 2021
Tobacco, Retail, Specialty, IG, NANO, VINCI, Technology, POD, TikTok, Nicotine, Neon, Lists of people executed in the United States, Color, Time, Internet, Facebook, MOD, Multimedia, RAP, ARGUS, Infinite, Drag, Sintering

On the 18th of October, VOOPOO officially announced the overseas launch of the new DRAG NANO 2 product.

Key Points: 
  • On the 18th of October, VOOPOO officially announced the overseas launch of the new DRAG NANO 2 product.
  • After two years, the second generation of the NANO series has been launched, with a striking design and multiple advanced technologies such as three gears of output and top e-juice filling.
  • VOOPOO has officially confirmed that the document refers to the new DRAG NANO 2, and that the leaking of it was an oversight during the company's relocation process.
  • The NANO 2 continues the classic angular design of the Drag series, with the materials of zinc alloy, it will bring you ultimate metallic hand feeling.